Brintellix News and Research

RSS
FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA approves Brintellix drug to treat depressive disorder in adults

FDA approves Brintellix drug to treat depressive disorder in adults

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.